Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Paolo Strati, MD, Mariela Sivina, PhD, Ekaterina Kim, PhD, Michael J. Keating, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD

Blood (2018) 132 (Supplement 1): 1873.

https://doi.org/10.1182/blood-2018-99-111044

Published: 2018

Journal Articles

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

Jan A. Burger, MD PhD, Mariela Sivina, PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan Kadia, MD, Zeev Estrov, MD, Graciela Nogueras González, Xuelin Huang, PhD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Lynette Alexander-Williams, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, William G Wierda, MD PhD, Michael J. Keating, MD

Blood (2017) 130 (Supplement 1): 427.

https://doi.org/10.1182/blood.V130.Suppl_1.427.427

Published: 2017

Journal Articles

CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients

Mariela Sivina, PhD, Ekaterina Kim, PhD, Claire Pacelli, Michael J. Keating, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3002.

https://doi.org/10.1182/blood.V130.Suppl_1.3002.3002

Published: 2017

Journal Articles

Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia

Simon Schliffke, MD, Mariela Sivina, PhD, Ekaterina Kim, PhD, Benjamin Thiele, MD, Nuray Akyüz, PhD, Clemens Falker-Gieske, PhD, Toni Thenhausen, Artus Krohn-Grimberghe, PhD, Carsten Bokemeyer, MD, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Michael J. Keating, MD, Jan A. Burger, MD PhD, Mascha Binder, MD

Blood (2016) 128 (22): 4402.

https://doi.org/10.1182/blood.V128.22.4402.4402

Published: 2016

Journal Articles

IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment

Elisa ten Hacken, PhD, Mariela Sivina, PhD, Li Ping, PhD, Susan O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Michael J. Keating, MD, Cristina Scielzo, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Jan A. Burger, MD PhD

Blood (2015) 126 (23): 2915.

https://doi.org/10.1182/blood.V126.23.2915.2915

Published: 2015

Journal Articles

Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma

Jan A. Burger, MD PhD, Kelvin Li, PhD, Michael Keating, MBBS, Mariela Sivina, PhD, Alessandra Ferrajoli, MD, Annette Jalayer, RN, Xuelin Huang, Hagop M. Kantarjian, MD, William G. Wierda, MD PhD, Susan O'Brien, MD, Marc Hellerstein, MD PhD, Scott Turner, PhD, Claire Emson, PhD, Shih-Shih Chen, PhD, Xiao-Jie Yan, MD PhD, Nicholas Chiorazzi, MD

Blood (2014) 124 (21): 326.

https://doi.org/10.1182/blood.V124.21.326.326

Published: 2014

Journal Articles

Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation

Mariela Sivina, PhD, Lillian Werner, Laura Rassenti, PhD, William G. Wierda, MD PhD, Michael J. Keating, MD, Susan O'Brien, MD, Donna Neuberg, ScD, Thomas J. Kipps, MD PhD, Jan A. Burger, MD PhD

Blood (2014) 124 (21): 5640.

https://doi.org/10.1182/blood.V124.21.5640.5640

Published: 2014

Journal Articles

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Mariela Sivina, PhD, Robert J. Kreitman, MD, Evgeny Arons, PhD, Joseph J. Buggy, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 1802.

https://doi.org/10.1182/blood.V120.21.1802.1802

Published: 2012

Journal Articles

Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.

Koichi Takahashi, MD, Mariela Sivina, PhD, Yasuhiro Oki, MD, Luis E Fayad, MD, Sattva S. Neelapu, MD, Larry W. Kwak, MD, PhD, Lianchun Xiao, Xuelin Huang, PhD, Kai Fu, MD, PhD, Wing Chung Chan, MD, Julie M Vose, MD, MBA, Hagop M. Kantarjian, MD, Michael Keating, MD, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 2709.

https://doi.org/10.1182/blood.V120.21.2709.2709

Published: 2012

Journal Articles

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

Mariela Sivina, PhD, Robert J. Kreitman, MD, Amnon Peled, PhD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 1760.

https://doi.org/10.1182/blood.V118.21.1760.1760

Published: 2011

Journal Articles

The PI3 Kinase δ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures.

Stefania Fiorcari, Wells S Brown, Bradley W McIntyre, PhD, Susan O'Brien, MD, Mariela Sivina, PhD, Julia Hoellenriegel, William G. Wierda, MD, PhD, Michael J Keating, MD, Roberto Marasca, Brian J. Lannutti, PhD, Zeev Estrov, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 1769.

https://doi.org/10.1182/blood.V118.21.1769.1769

Published: 2011

NARROW

Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)

CXCL13 (BCA-1) Plasma Levels Are a Useful Biological Marker for Disease Progression in Chronic Lymphocytic Leukemia (CLL) Patients

Opposite Effects of Bruton Tyrosine Kinase (BTK) Inhibitor Therapy with Ibrutinib and FCR Chemo-Immunotherapy on the Normal B Lymphocyte Repertoire in Patients with Chronic Lymphocytic Leukemia

IgM and IgD Receptors Differentially Contribute to CLL Survival and Chemokine Secretion: Implications for CLL Biology and Treatment

Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma

Dynamics Changes in CCL3 and CCL4 Plasma Chemokine Levels in Patients with Chronic Lymhocytic Leukemia (CLL) Managed with Observation

Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL

Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.

Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors

The PI3 Kinase δ Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only